Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular; and pellets for excipient, antiulcerative, diabetes drug, anti-inflammatory, and anti-anginals. The company is also involved in the process development, qu… Read more
Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.03 Billion CNY
Based on the latest financial reports, Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) has total liabilities worth CN¥1.03 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Total Liabilities Trend (2011–2024)
This chart illustrates how Zhuhai Rundu Pharmaceutical Co Ltd Class A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhuhai Rundu Pharmaceutical Co Ltd Class A Competitors by Total Liabilities
The table below lists competitors of Zhuhai Rundu Pharmaceutical Co Ltd Class A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qingdao NovelBeam Technology Co. Ltd. A
SHG:688677
|
China | CN¥253.36 Million |
|
Guangdong Huiyun Titanium Industry
SHE:300891
|
China | CN¥1.77 Billion |
|
Moso Power Supply Technology Co Ltd
SHE:002660
|
China | CN¥758.07 Million |
|
US Century Bank
NASDAQ:USCB
|
USA | $2.59 Billion |
|
Hengerda New Materials (Fujian) Co. Ltd.
SHE:300946
|
China | CN¥436.68 Million |
|
CLS Holdings plc
PINK:CLIHF
|
USA | $1.06 Billion |
|
PT Hanjaya Mandala Sampoerna Tbk
PINK:PHJMF
|
USA | $21.51 Trillion |
|
Firstrand Ltd
JSE:FSR
|
South Africa | ZAC2.45 Trillion |
Liability Composition Analysis (2011–2024)
This chart breaks down Zhuhai Rundu Pharmaceutical Co Ltd Class A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.49 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhuhai Rundu Pharmaceutical Co Ltd Class A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhuhai Rundu Pharmaceutical Co Ltd Class A (2011–2024)
The table below shows the annual total liabilities of Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.04 Billion | -0.68% |
| 2023-12-31 | CN¥1.05 Billion | -3.83% |
| 2022-12-31 | CN¥1.09 Billion | +36.76% |
| 2021-12-31 | CN¥797.28 Million | +67.66% |
| 2020-12-31 | CN¥475.54 Million | +23.07% |
| 2019-12-31 | CN¥386.39 Million | +44.65% |
| 2018-12-31 | CN¥267.13 Million | +23.01% |
| 2017-12-31 | CN¥217.16 Million | -0.57% |
| 2016-12-31 | CN¥218.42 Million | +15.57% |
| 2015-12-31 | CN¥189.00 Million | +85.11% |
| 2014-12-31 | CN¥102.10 Million | -5.68% |
| 2013-12-31 | CN¥108.25 Million | +14.39% |
| 2012-12-31 | CN¥94.63 Million | +29.12% |
| 2011-12-31 | CN¥73.29 Million | -- |